Menu Search
Equities

Futura Medical PLC

GYX:FRA

Futura Medical PLC

Actions
  • Price (EUR)0.384
  • Today's Change0.00 / 0.00%
  • Shares traded3.98k
  • 1 Year change+22.29%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 07:16 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Futura Medical plc is a United Kingdom-based pharmaceutical company. The Company is engaged in the development and sale of pharmaceutical and healthcare products. It is focused on developing a portfolio of products based on its transdermal DermaSys technology. The DermaSys is designed to deliver clinically proven medical treatments via the skin. DermaSys platform with penetration and permeation enhancer components tailored for each product to suit the specific therapeutic indication and desired speed of onset and duration of action. Such targeted delivery offers an optimized profile in terms of dose, onset time and duration of effect. The Company's products include MED3000 and TPR100. The Company's lead product, MED3000, is a topical gel formulation treatment for erectile dysfunction (ED) through an evaporative mode of action. The Company has conducted a Phase III study using MED3000 in ED. The Company is also developing CBD100, which is a topical cannabidiol formulation.

  • Revenue in GBP (TTM)8.40m
  • Net income in GBP-3.75m
  • Incorporated2001
  • Employees12.00
  • Location
    Futura Medical PLC40 Occam RoadGUILDFORD GU2 7YGUnited KingdomGBR
  • Phone+44 148 368 5670
  • Fax+44 148 368 5671
  • Websitehttps://www.futuramedical.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.